Search the Newsreel

Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99%

Balyasny Asset Management and its affiliated entities have disclosed a beneficial ownership of 7,844,311 shares of Lexeo Therapeutics, Inc. (LXEO) common stock, representing 9.99% of the outstanding shares. This stake includes shares directly held by Atlas Diversified Master Fund and Atlas Private Holdings, with …

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake

Affinity Asset Advisors, LLC and Michael Cho have reported an 8.4% beneficial stake in Lexeo Therapeutics (LXEO) through an amended Schedule 13G filing. This includes 6,674,913 shares of common stock, with 867,302 shares issuable upon warrant exercise, as of June 30, 2026. The reporting …

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

Hennion & Walsh Asset Management Inc. has initiated a new position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), purchasing 265,697 shares valued at approximately $1.24 million during the second quarter. This investment comes as institutional investors collectively own 60.67% of the company. Lexeo Therapeutics recently reported …

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

Lexeo Therapeutics (NASDAQ:LXEO) announced its latest quarterly earnings, reporting a loss of $0.30 per share, which matched analysts' consensus estimates. Following the announcement, the stock saw a 4.6% increase to $5.00, although it remains significantly below its 12-month high. Analysts maintain a "Buy" rating …

Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History

Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com

The article reports that Lexeo Therapeutics Inc. filed a Form 8K on August 12. It briefly mentions the company name and filing date, without providing further details on the content of the filing. The article is very short and seems to act as a …

Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary

Lexeo Therapeutics, Inc. reported a net loss of $25.9 million and an EPS of $(0.30) for the second quarter of 2026, remaining pre-revenue. The company highlighted clinical progress for LX2006 and LX2020, including the initiation of a pivotal trial for LX2006 and RMAT designation …

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics announced its second quarter 2026 financial results and operational highlights, focusing on advancements in its gene therapy pipeline. Key achievements include the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 in Friedreich ataxia cardiomyopathy and the FDA's RMAT designation for LX2020 …

LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway

Lexeo Therapeutics (LXEO) is focused on gene therapies for rare cardiac diseases, with a pipeline that includes two clinical-stage and two preclinical programs. Its lead candidates, LX2006 and LX2020, are showing promising efficacy and safety data, with key milestones anticipated. The company reports strong …

Lexeo Therapeutics advances gene therapy and gains RMAT status

Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash

Lexeo Therapeutics (LXEO) Earnings Date and Reports 2026

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

Dimensional Fund Advisors LP significantly increased its stake in Lexeo Therapeutics, Inc. during the first quarter, now owning 1.41% of the company's shares. Despite this institutional interest, Lexeo insiders, including the CEO, recently sold shares primarily to cover tax obligations on vested equity awards. …

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average "Buy" rating from nine brokerage firms, with an average 12-month price target of $18.75. Despite insider sales totaling $280,089 over the past three months, institutional investors collectively own 60.67% of the company. The company's stock currently …

Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lexeo Therapeutics Inc (LXEO) has an earnings forecast score of 9.20, ranking 9th in its industry. Analysts have set an average price target of $18.50, with a strong buy recommendation. The company's previous EPS was -$0.27, and the next quarter's EPS is expected to …

Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday

Lexeo Therapeutics (LXEO) is expected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts projecting a loss of $0.30 per share. The company, currently unprofitable with a market capitalization of $349 million, has a "Buy" consensus rating and …

Lexeo's LX2020 Secures FDA RMAT Tag For PKP2-Associated Arrhythmogenic Cardiomyopathy

(RTTNews) - Lexeo Therapeutics (LXEO) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). PKP2-associated arrhythmogenic cardiomyopathy is a rare inherited heart disease caused …

Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy LX2020, intended for PKP2-associated arrhythmogenic cardiomyopathy. This designation was granted based on positive interim data from the ongoing Phase I/II HEROIC-PKP2 trial. LX2020 previously received FDA Orphan Drug and …

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Lexeo Therapeutics (NASDAQ:LXEO) by 9.7% in the first quarter, selling over 533,000 shares but still retaining a significant holding. Meanwhile, other institutional investors like Affinity Asset Advisors and Orbimed Advisors increased their positions in the clinical-stage …

Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis

Lexeo Therapeutics Inc (LXEO) currently holds a financial score of 5.73, placing it 326 out of 384 in the Biotechnology & Medical Research industry, indicating weak financial status and low operating efficiency. The report highlights that relevant financial data for Quality of Earnings, Operational …

Lexeo Therapeutics Inc (LXEO) Institutional Confidence

Lexeo Therapeutics Inc (LXEO) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 25.76% quarter-over-quarter, with the largest holder being Bill Nygren | OAKMX. Several other major institutional shareholders …

Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an in-depth look into the shareholder structure of Lexeo Therapeutics Inc (LXEO), detailing its major institutional shareholders and their respective proportions. It also categorizes shareholders by type (e.g., Hedge Fund, Investment Advisor) and presents historical institutional shareholding data and recent shareholder …

Lexeo Therapeutics Inc (LXEO) Cash Flow

This article provides a detailed cash flow statement for Lexeo Therapeutics Inc (LXEO), covering annual and quarterly data across operating, investing, and financing activities. It presents financial figures with year-over-year percentage changes for multiple quarters, alongside explanations of what each cash flow category represents …

Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lexeo Therapeutics Inc (LXEO) stock information, focusing on its dividend and stock split history. It notes that no dividend data is available, with zero dollars distributed over the past five years. The page also presents current trading information …

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP

Orbimed Advisors LLC Purchases 1,477,450 Shares of Lexeo Therapeutics, Inc. $LXEO

Lexeo Therapeutics Inc (LXEO) Income Statement

This article presents the quarterly and annual income statements for Lexeo Therapeutics Inc (LXEO), offering detailed financial data such as revenue, operating expenses, and net income from Q1 2022 through Q1 2026. It highlights the company's financial performance and includes FAQs to guide users …

Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Lexeo Therapeutics Inc (LXEO), noting its current valuation score of 6.63, which ranks it 313 out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -4.14, while relevant data for …

LXEO|Lexeo Therapeutics Inc|Price:4.660|Chg%:-0.050

This article provides a detailed stock analysis of Lexeo Therapeutics Inc (LXEO), highlighting its fundamentals, growth potential, and valuation. The company has weak fundamentals but high growth potential, and its stock is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have …

Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Lexeo Therapeutics Inc (LXEO) has a current risk assessment score of 4.33, ranking 84 out of 386 in the Biotechnology & Medical Research industry. The company's beta value is 0.00, indicating it tends to underperform during upward markets but decline less during downward markets. …

Affinity Asset Advisors LLC Increases Stock Position in Lexeo Therapeutics, Inc. $LXEO

LXEO Forecast — Price Target — Prediction for 2027

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation